Summary: Serial serum determinations of the tumour associated antigens carcinoembryonic antigen, tissue polypeptide antigen, CA 19-9, CA 15-3 and CA 125 were performed on 70 patients who were undergoing, or had undergone renal transplantation.
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The tumour markers studied were: tissue polypeptide antigen, as this is known to be eliminated renally (1, 2) , carcinoembryonic antigen and the tumour associated antigens CA 19-9, CA 15-3 and CA 125. Similar studies, but using single samples from patients with chronic renal failure and under renal haemodialysis, have already been published (7) (8) (9) , although the results are often different from those found in the present study.
The observation period covered in this study ranged from one week pre-transplant and 708 days after transplantation.
Materials and Methods

Materials
Immunoassay kits were purchased from Byk-Sangtec (Dietzenbach, D.) for tissue polypeptide antigen (TPA LIA-mat, immunoluminometric assay) and from Boehringer-Mannheim (Mannheim, Germany) for carcinoembryonic antigen and the tumour associated antigens CA 19-9, CA 15-3 and CA 125 (Enzymun-Test® CEA, CA 19-9, CA 15-3 and CA 125, immunoenzymometric assays).
Methods
All analytes were measured according to the manufacturers' instructions. The tissue polypeptide antigen assay was measured with a 250 sample semi-automated luminometer (E.G. & G. Berthold, Wildbad, Germany). The remaining analytes were measured on the Enzymun-Test® System ES-300 (Boehringer, Mannheim). Table 1 shows the reference ranges for these analytes as established in the routine laboratory of the author (W. G. W.).
Patients
Seventy patients were studied prospectively over a two year period. All patients who were admitted to the renal transplant unit were taken into the study. The study was carried out between 1989 and 1991 as part of an ongoing study mainly concerned with the evaluation of urinary proteins in such patients, the results of which have already been published in part (10) (11) (12) .
The five tumour markers were measured daily so long as the patient was in hospital. This covered the peri-and post-transplant periods, as well as periods where complications occurred, usually in the form of rejection episodes, but also in cases of cytomegalovirus infection.
The observation period was from directly before transplantation up to 708 days post-operatively, although the daily monitoring usually covered a period between 14 and 35 days.
Statistics
Statistics were kept to a minimum, the 2-and 4-field chi-square test being used when required. The 95th percentile was taken as the upper limit as many of the subjects had tumour marker concentrations below the lower detection limit of the assays.
Notes upon the analytes measured
Tissue polypeptide antigen -TPA
This marker is known to be eliminated renally, elevated concentrations being encountered in oliguric and anuric patients (1, 2) . After onset of diuresis, tissue polypeptide antigen coriĉ entrations returned to normal or near normal. Impairment of renal function, for example as in a rejection episode, inevitably led to increased tissue polypeptide antigen concentrations, which correlated with the degree and duration of the episode.
Carcinoembryonic antigen -CEA
This "classical" tumour marker is often seen to be slightly elevated in patients on chronic haemodialysis (3), and was studied here for this reason.
Tumour associated antigens -CA 19-9, CA CA 125 These markers are known to be elevated in certain patients with impaired renal function (1 -3, 7, 9), although the reports from the literature differ, even for the same marker. All 3 markers are present in epithelial cells.
Assay reproducibility
The median inter-assay coefficients of variation for the assays carried out on the Enzymun-Test® System ES-300 were less than 5% over the whole measuring range (derived from 5 control sera covering the whole standard curve for each assay, measured in at least 20 assays) so that sequential analysis of the samples (inclusion in routine assays) was carried out. No difference was seen when all samples from a single patient analysed in one assay were compared with the results obtained as above.
As this was not the case for tissue polypeptide antigen, the batch analysis of all samples from a single patient was performed as far as was possible. The median inter-assay coefficient of variation for tissue polypeptide antigen was 8.7% (derived from 20 assays using the same batch of control sera at three concentrations between 50 and 480 U/l).
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Results
General comments
Patients with no clinical complications post-operatively did not necessarily have normal tumour marker concentrations in serum.
Only one patient presented with a clinically/histologically confirmed tumour post-operatively, namely a non-secreting B-cell lymphoma, which was successfully treated.
No apparent correlation was found between the actual clinical condition and the appearance of elevated tumour markers, with the exception of tissue polypeptide antigen and carcinoembryonic antigen. Correlations considered were: transplant rejection episodes, viral/ bacterial infections, medication regimes and cyclosporin toxicity.
Specific cases
Parallel changes in at least 3 of the four markers (excluding tissue polypeptide antigen)
Six of 70 patients showed parallel changes in at least three of the markers. 4/6 of these patients had at least one elevated tumour marker. Figures la and Ib are given as examples of this group.
All tumour concentrations normal in patients with a clinically uneventful post-transplant period
Eight of 70 patients had normal concentrations of all 5 analytes after an uneventful renal transplant operation (figs. 2a and 2b). Days after onset of diuresis during this time. It is intersting to note that although the lymphoma was cured (normal blood smear), the CA 19-9 and tissue polypeptide antigen concentrations remained elevated. The serum values on day 708 post op. were: tissue polypeptide antigen 178 U/l, CA 19-9 113 kU/l, CA 15-3 30 kU/1, CA 125 < 6 kU/1, carcinoembryonic antigen 3.6 μg/l. The concentrations of CA 15-3 were more or less constant and were borderline (20-32 kU/1). CA 125, although borderline during the first observation period (18 -34 kU/1), was below the detection limit of the assay almost two years later. Tissue polypeptide antigen remained ele^· vated, despite a normal diuresis. The patient had no signs of malignant disease on day 708, her transplant functioned normally and there were no clinical complications.
Two cases of transplant rejection (figs. 6a and 6b) Case 1.
After intermittent onset of diuresis'(days 2-10) the course was uneventful until day 24 when the first signs of rejection were seen (glomerular proteinuria). After successful treatment with methyl prednisolone, the patient was discharged οη* day 43. A second rejection episode was confirmed on day 69, which was successfully treated, the patient being discharged on day 106. During the second rejection episode, CA 19-9 This patient showed no complications until day 55 when transplant rejection signs were seen. After successful treatment (methyl prednisolone), the patient was dicharged (day 70), only to be readmitted on day 96 with similar symptoms. Drugs used for treatment of the second rejection episode included methyl prednisolone and anti-lymphocyte globulins.
The interesting point to note is again the large day to day variation in all tumour markers, with the exception of carcinoembryonic antigen, which remained below 2 μg/l throughout the study period. In contrast to case 1, the tissue polypeptide antigen concentrations oscillated between the upper limit of the reference range and values twice as high. During episodes, variations of up to 60 U/l occurred from day to day.
Correlation between elevated tumour markers and cytomegalovirus infection
There was no correlation between the incidence of an elevated tumour marker and a cytomegalovirus infection or cytomegalovirus-positive donor organ. This is in contrast to the isolated 2 -microglobulinuria seen in cytomegalovirus infections (10 p 12).
From the 37 patients, which were positive for cytomegalovirus (either as an infection (17/37) or in the constellation donor cytomegalovirus positive 36/37), 21 had at least one elevated tumour marker (excluding tissue polypeptide antigen). From the remaining 33 patients, who had no cytomegalovirus infection and whose transplanted kidney was also cytomegalovirus negative, 21 had at least one elevated tumour marker. The difference between the groups was not statistically significant.
Discussion
From this study it cannot be claimed that elevated tumour markers in renal transplant patients is indicative of malignant disease. Only one out of seventy patients had a transient malignancy in the form of a non-secreting B-cell lymphoma, which was no longer evident after treatment.
There was no "wash-out" of tumour associated antigens (CA) at the onset of diuresis. As expected, tissue polypeptide antigen concentrations sank after onset of diuresis. The same was evident for carcinoembryonic antigen, where pre-operatively elevated values (17/70 patients) fell to within the reference range for healthy individuals during 9 -14 days after onset of diuresis in 12/17 cases. Of the remaining 5 cases, 3 were concomitant with elevated CA 19-9 concentrations. Carcinoembryonic antigen concentrations above 12 μg/l were not seen pre-operatively.
Although it is known that almost all "tumour markers" can be elevated in non-malignant disease (1) (2) (3) (4) (13) (14) (15) , it remains unclear from the literature as to the role of renal insufficiency and the post renaltransplant period in the elevation of tumour markers, which are not purely renally excreted.
Cases et al. (3) describe elevated tumour marker concentrations in 30 patients with chronic renal failure and 36 patients on haemodialysis. They found elevated carcinoembryonic antigen in one third of the chronic renal failure group and in 47% of the patients undergoing haemodialysis. These figures are considerably higher than those found in the present study, even when considering the pre-transplant values. The same authors found elevated CA 125 concentrations in 18% of the chronic renal failure and 36% of the haemodialysis patients, which compare well with the figures in this study (41%). Cases and coworkers (3) also found elevated concentrations of carcinoem-bryonic antigen, CA 50 (similar in structure to CA 19-9) and neuron-specific enolase and squamous cell carcinoma-antigen in chronic renal failure, which led the authors to postulate these markers as being unreliable in such patients. CA 15-3 and CA 19-9 elevations were much rarer, which coincides with the findings of the present study.
Zeferos et al. (7) have studied tumour markers in renal transplant patients and compared the results with those from healthy controls and patients on chronic haemodialysis. They found that concentrations of otj-foetoprotein, CA 15-3 and carcinoembryonic antigen were significantly higher in haemodialysis patients than in controls or renal transplant patients. In contrast, CA 125 and CA 19-9 concentrations were not different in all three groups. Although the findings of the present study are in agreement, as far as carcinoembryonic antigen is concerned, they differ with respect to CA 19-9 and CA 125. Zeferos and coworkers concluded that the two latter markers "can be considered as reliable tumour markers in patients undergoing haemodialysis or kidney transplantation". The same authors query the significance of elevated CA 15-3 concentrations after renal transplantation.
Filella et al. (8) suggest a renal metabolism for carcinoembryonic antigen because of elevated concentrations found in renal insufficiency, although renal elimination could equally well be postulated to explain elevated carcinoembryonic antigen in such patients. The "wash-out" of carcinoembryonic antigen after onset of diuresis, as seen in this study, would tend to support the elimination theory.
Ammon and coworkers (9) found no difference in CA 125 concentrations in healthy subjects and patients with renal insufficiency, although elevated carcinoembryonic antigen (24% > 5 ^), CA 15-3 (20% > 30 kU/1) and CA 19-9 (14% > 40 kU/1) concentrations were seen in the same group of patients. As malignant disease had been excluded, Ammon and coworkers concluded that "it seemed likely that the terminal renal insufficiency plays a causal role" in the elevation of tumour markers seen in this group.
In the present study, which comprised over 8500 single measurements of the 5 tumour markers investigated during a long-term study encompassing two years, the results shed some light on the pre-, peri-and postoperative periods in patients subjected to renal transplantation. There are, however many questions still to be answered as to why certain patients have elevated concentrations of certain tumour markers with no evidence of malignant disease.
In addition, it must be stated although the antibodies for the different commercial kits for the tumour associated antigen (CA) tumour markers studied here are supplied by the same firm, this does not guarantee the same results for the same analyte, if different kits are used. This is especially true for CA 19-9 and CA 72-4 (Wood, unpublished observations).
The use of different reference points for defining "normal" and "elevated" values further complicates comparison of results. There are considerable differences between the reference range found for a defined population, the "normal ranges" given by the kit producer, and the "cut-off values for defined diagnostic specificity and sensitivity.
The conclusions which can be made from this study are that single isolated determinations of CA 125 and CA 19-9 are not reliable indicators of malignancy in renal transplant patients. Because isolated CA 15-3 concentrations are also found in these patients, care must be taken in interpreting elevated concentrations.
Tissue polypeptide antigen concentrations fluctuate with diuresis, a point known for several years (1, 2) but still not mentioned in the kit instructions.
Carcinoembryonic antigen concentrations may be slightly elevated before transplantation, but usually return within the reference range for healthy individuals shortly after onset of diuresis, although concomitantly elevated concentrations of carcinoembryonic antigen and CA 19-9 pre-operatively do not always fall after transplantation and onset of diuresis.
Although some categorisation and grouping of results was possible, the study emphasised the individuality of the results from each patient, a point which must be borne in mind when interpreting tumour marker results from such patients.
